阅读说明：本技术 黄芪黄精当归组合物及其在调节肠道微生物中的用途 (Astragalus membranaceus, rhizoma polygonati and angelica sinensis composition and application thereof in regulating intestinal microorganisms ) 是由 魏来 梁桥星 葛小菲 于 2018-06-20 设计创作，主要内容包括：本发明提供一种黄芪黄精当归组合物,黄芪黄精当归组合物在调节肠道微生物中的用途及其在制备药物中的应用,所述药物为治疗与肠道菌群紊乱相关疾病的药物。(The invention provides an astragalus, polygonatum and angelica composition, application of the astragalus, polygonatum and angelica composition in regulating intestinal microorganisms and application of the composition in preparing a medicament, wherein the medicament is a medicament for treating diseases related to intestinal flora disorder.)

1. A Chinese medicinal composition comprises radix astragali, rhizoma Polygonati and radix Angelicae sinensis.

2. The traditional Chinese medicine composition as claimed in claim 1, wherein the raw material medicines comprise 15-60 parts by weight of astragalus membranaceus, rhizoma polygonati and angelica sinensis: 10-40: 10-40.

3. The traditional Chinese medicine composition according to claim 2, wherein the raw material medicines comprise 30-60 parts by weight of astragalus membranaceus, rhizoma polygonati and angelica sinensis: 20-40: 20-40.

4. Use of the Chinese medicinal composition of claim 1 for regulating intestinal microorganisms.

5. The use of the herbal composition of claim 4 for modulating gut microbiome, wherein said modulating gut microbiome is a selective increase in the number of bacteria in the gut selected from the group consisting of: enterobacter (Enterobacter), Lactobacillus (Lactobacillus), Streptomyces (Streptomyces), Stem (Caulobacter), Desulvibrio (Desulfovibrio), Actinidium (Atopobium), Corynebacterium (Corynebacterium), Treponema (Treponema), Helicobacter (Helicobacter), Bacteroides (Bacteroides), Candida (Nostoc), Marinobacter (Marinobacter), Cellulobacterium (Fibrobacter), Brevundimonas (Brevundimonas), Porphyromonas (Porphyromonas), Achromobacter (Achromobacter), Bifidobacterium (Bifidobacterium), Prevotella (Prevotella), or combinations of two or more thereof.

6. The use of a Chinese medicinal composition according to claim 5 for the regulation of gut microbiota, wherein said bacteria are selected from the group consisting of: one or more of Enterobacter, Lactobacillus, and Streptomyces.

7. The use of the composition according to claim 4 for modulating gut microbiome, wherein the modulating gut microbiome is a selective inhibition of the number of bacteria in the gut selected from the group consisting of: shigella (Shigella), Streptococcus (Streptococcus), Haemophilus (Haemophilus), Ruminococcus (Ruminococcus), vibrio butyricum (Butyrivibrio), pseudovibrio butyricum (pseudobutyrothyrivibrio), Lachnospiraceae (Lachnospiraceae), Enterococcus (Enterococcus), Eubacterium (Eubacterium), brachospira (Brachyspira), coprinus (coprobacterium), Clostridium (Clostridium), Parabacteroides (Parabacteroides), anaerobium (anaerobacterium), coprinus (Coprococcus), or combinations of two or more thereof.

8. The use of a Chinese medicinal composition according to claim 7 for the regulation of gut microbiota, wherein said bacteria are selected from the group consisting of: one or more of Shigella, Streptococcus, Haemophilus, butyric acid vibrio, Callospiroceae, Brevibacillus, and Clostridium.

9. The use of the composition of claim 4 for modulating gut microbiome, wherein said modulating gut microbiome is a selective inhibition of the amount of a virus in the gut selected from the group consisting of: streptococcal virus (Streptococcus virus), enterococcal phage (enterococcal phage), Lactobacillus phage (Lactobacillus phage), and enterobacter phage (Enterobacter phage).

10. Use of a Chinese medicinal composition according to claim 1 for the preparation of a medicament for the treatment of a disease associated with a disturbed intestinal flora.

11. The use of a Chinese medicinal composition according to claim 10 in the preparation of a medicament, wherein the disease is selected from: chronic diarrhea, constipation, obesity, food allergy, pancreatitis, liver injury, intestinal inflammation, irritable bowel syndrome, peptic ulcer, renal calculus, diabetes, rheumatoid arthritis, Behcet's disease, cardiovascular disease, cerebrovascular disease, tumor, paralysis, eye disease, multiple sclerosis, ankylosing spondylitis, Parkinson's disease, anxiety, autism, depression, chronic fatigue.

Technical Field

The invention belongs to the field of medicine and health care, and particularly relates to application of a composition containing astragalus, rhizoma polygonati and angelica sinensis in improving and regulating intestinal microorganisms.

Background

A large number of microorganisms live in the human body, and particularly 1000-1150 kinds of bacteria in the intestinal tract of the human body, about 100 trillion, are the most important 'endogenous environmental factors' of the human body, and the number of the bacteria is about 10 times of the number of the cells of the human body. Under normal conditions, the intestinal microorganisms are in a dynamic equilibrium ecological environment, the normal flora not only plays an irreplaceable role in digestion, immunity and virus resistance, but also the change of the intestinal microorganisms has a very close relationship with the health of the body or the occurrence of diseases, particularly some chronic diseases. In the modern social environment, people have high working strength and high living pressure, and the human body is in various stress states for a long time, so that the intestinal microorganisms are often disordered and are shown as abnormal changes of the types, the quantities, the proportions and the biological characteristics of the intestinal microorganisms. Dysbacteriosis, in turn, impairs the barrier function of the intestinal tract by affecting the absorption of nutrients by the body, further aggravating the disease and creating a vicious cycle. Researches prove that the pathogenesis of various diseases of human bodies such as long-term diarrhea, constipation, intestinal inflammation, digestive tract ulcer, diabetes, hypertension, hyperlipidemia, tumor and the like is closely related to intestinal microorganisms. Although it is not clear whether the metabolic disease is caused by a change in the intestinal microbial flora or caused by a change in the intestinal microbial flora, it is certain that: by changing the composition of the intestinal microbial flora, the health of a human body is influenced, and meanwhile, the intestinal microbial flora can also provide help for treating certain diseases. Currently, gut microbiota have been considered as potential therapeutic targets for a variety of diseases.

Patent document CN 106620189 a provides a method for improving intestinal microbial structure, and its application in the process of preparing medicines, nutraceuticals, health products, foods, beverages, etc. The invention finds out intestinal bacteria groups closely related to host metabolism by adopting a high-throughput sequencing technology and a multivariate statistical method, for example, bacteria producing short-chain fatty acids in intestinal tracts are mostly beneficial bacteria, and the intestinal bacteria can play roles in resisting inflammation, protecting intestinal barrier function, regulating human metabolism and immunity and the like by increasing the content of the short-chain fatty acids in the intestinal tracts. Short chain fatty acid producing bacteria include blautia, Allobaculum, prevotella, bacteroides or Butyricimonas. Most of the bacteria producing endotoxin in the intestinal tract are harmful bacteria, and the bacteria can cause inflammation, damage the intestinal barrier function, cause metabolism and immune disorder of human bodies and the like by increasing the content of the endotoxin in the intestinal tract. Endotoxin-producing bacteria include bacteria of the phylum proteobacteria.

The beneficial gut bacteria discovered by scientists to date fall into three general categories, which include: lactobacillus species (e.g., lactobacillus acidophilus, lactobacillus casei, lactobacillus jensenii, lactobacillus raman, etc.); bifidobacterium (such as Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium ovorans, Bifidobacterium thermophilum, etc.); gram-positive cocci (e.g. faecal streptococci, lactococcus, intermediate streptococci, etc.).

The human biology is composed of two parts, the human genome and the human microbiome, wherein the change of the human genome is extremely difficult, but the change of the microbial composition in the human intestinal tract is relatively easy. At present, high-calorie diet and fast-paced life cause intestinal microorganism disorder of a part of people, most people can select diet adjustment unless emergency occurs, and researches show that some traditional Chinese medicines and some food with homology of medicine and food can adjust intestinal microorganisms of human bodies or animals. For example, patent document CN 105596445 a relates to the use of cortex moutan and radix paeoniae rubra in regulating intestinal microorganisms, and the inventor finds that the cortex moutan and radix paeoniae rubra not only can regulate the intestinal microorganisms, but also has no side effect and can be taken for a long time. Also for example, patent document CN 102987383B provides a composition consisting of a food product that is both edible and medicinal, said composition being useful for balancing the intestinal microbial structure in a subject and for improving metabolic syndrome.

In the invention, the inventor makes a relevant study on whether the composition containing astragalus, rhizoma polygonati and angelica can regulate intestinal microorganisms. Astragalus root, radix astragali, mild in nature, sweet in taste, enters lung, spleen, liver and kidney meridians, and has the functions of enhancing organism immunity, protecting liver, promoting urination, resisting aging, resisting stress, lowering blood pressure and broad antibacterial action. The traditional Chinese medicine composition is clinically used for treating hypertension, ischemic heart disease, acute glomerulonephritis, helicobacter pylori positive gastric ulcer, psoriasis, diabetes, chronic rhinitis, osteoporosis and the like. Rhizoma polygonati is neutral in nature and sweet in taste, enters spleen channels, lung channels and kidney channels, and has the effects of tonifying qi and yin, strengthening spleen, moistening lung and tonifying kidney. Pharmacological research shows that the sealwort has the functions of resisting pathogenic microorganisms, resisting fatigue, resisting oxidation, delaying senility, resisting virus and inhibiting the increase of blood sugar. Dang Gui is warm in nature and sweet and pungent in flavor, and enters heart, liver and spleen meridians, and its root can be used as a medicine, which is one of the most commonly used Chinese herbs. The angelica mainly contains sucrose, various amino acids, volatile oil, n-butene, lactone, nicotinic acid, ferulic acid and hemiterpene compounds, and also contains vitamin A, vitamin E, volatile oil, arginine and various minerals, and is commonly used for enriching blood and activating blood, regulating menstruation and relieving pain, moistening dryness and lubricating intestines.

Both patent documents CN 201510008559.3 and CN 201610212026.1 relate to the preparation of health products or health wine by mixing radix astragali, rhizoma Polygonati, and radix Angelicae sinensis with other Chinese medicinal materials. The inventor does not find the prior art related to the application of the astragalus membranaceus, polygonatum kingianum and angelica composition in regulating intestinal microorganisms by searching, so that the inventor conducts detailed research on whether the astragalus membranaceus, polygonatum kingianum and angelica composition can regulate intestinal flora and specific improved strains.

Disclosure of Invention

In the invention, the inventor researches and discovers that the composition containing astragalus, rhizoma polygonati and angelica sinensis can obviously improve the quantity of beneficial bacteria in intestinal tracts, inhibit the quantity of harmful bacteria and regulate intestinal microorganisms. At present, no research and report about the regulation of intestinal microorganisms by the composition of astragalus, polygonatum and angelica is found.

Therefore, one object of the present invention is to provide a composition comprising astragalus, polygonatum and angelica; the invention also aims to provide the application of the composition of astragalus, polygonatum and angelica in regulating intestinal microorganisms; the invention also aims to provide application of the composition of astragalus membranaceus, rhizoma polygonati and angelica sinensis in preparation of medicines for treating diseases related to intestinal flora disorder.

The invention provides a traditional Chinese medicine composition, and raw material medicines of the traditional Chinese medicine composition comprise astragalus membranaceus, rhizoma polygonati and angelica sinensis.

The invention provides a traditional Chinese medicine composition, which comprises raw material medicines of astragalus, rhizoma polygonati and angelica.

In the traditional Chinese medicine composition, the raw material medicines of the astragalus, the rhizoma polygonati and the angelica are 15-60 parts by weight: 10-40: 10-40.

Preferably, the raw material medicines comprise 30-60 parts by weight of astragalus membranaceus, rhizoma polygonati and angelica sinensis: 20-40: 20-40.

In the preferred embodiment of the invention, the traditional Chinese medicine composition comprises 15 parts of astragalus, 10 parts of rhizoma polygonati, 10 parts of angelica or 30 parts of astragalus, 20 parts of rhizoma polygonati, 20 parts of angelica or 60 parts of astragalus, 40 parts of rhizoma polygonati and 40 parts of angelica.

The traditional Chinese medicine composition is prepared by mixing medicinal powder or extracts of raw material medicines.

Preferably, the traditional Chinese medicine composition further comprises pharmaceutically acceptable auxiliary materials, wherein the auxiliary materials are selected from the following components: carrier, diluent, adhesive, lubricant and wetting agent.

Preferably, the dosage form of the traditional Chinese medicine composition is selected from: tablet, capsule, pill, injection, inhalant, buccal tablet, suppository, emulsion, nanoparticle, gel, powder, suspension, cream, jelly, spray, etc.

Preferably, the Chinese medicinal composition can adopt an administration mode selected from the following modes: oral, enteral, subcutaneous, intramuscular, intravenous, nasal, transdermal, subconjunctival, intra-ocular, orbital, retrobulbar, retinal, choroidal, intrathecal and the like.

The invention provides application of a traditional Chinese medicine composition in regulating intestinal microorganisms.

The use of the Chinese medicinal composition in regulating intestinal microorganisms can be selectively increasing the number of bacteria in the intestinal tract, wherein the bacteria are selected from the following groups: one or a combination of two or more of Enterobacter (Enterobacter), Lactobacillus (Lactobacillus), Streptomyces (Streptomyces), Stem (Caulobacter), Desulvibrio (Desulfovibrio), Actinidium (Atopobium), Corynebacterium (Corynebacterium), Treponema (Treponema), Helicobacter (Helicobacter), Bacteroides (Bacteroides), Candida (Nostoc), Marinobacter (Marinobacter), Cellulobacter (Fibrobacter), Brevundimonas (Brevundimonas), Porphyromonas (Porphyromonas), Achromobacter (Achromobacter), Bifidobacterium (Bifidobacterium), Prevotella (Prevotella);

preferably, the bacteria are selected from: one or more of Enterobacter, Lactobacillus, and Streptomyces;

more preferably, the bacteria are selected from the group consisting of: microorganism strain, microorganism strain, microorganism strain, microorganism strain, microorganism strain, microorganism strain, strain, strain, strain, strain, strain, strain, strain, strain, strain, strain, strain, strain, strain, strain, strain, strain, strain, strain, strain, strain.

The use of the Chinese medicinal composition in regulating intestinal microorganisms can be selectively inhibiting the number of bacteria in the intestinal tract, wherein the bacteria are selected from the following groups: one or a combination of two or more of Shigella (Shigella), Streptococcus (Streptococcus), Haemophilus (Haemophilus), Ruminococcus (Ruminococcus), Vibrio butyricum (Butyrivibrio), Pseudovibrio butyricum (Pseudobutyryvibrio), Lachnospiraceae (Lachnospiraceae), Enterococcus (Enterococcus), Eubacterium (Eubacterium), Brevibacillus (Brachyspira), fecal bacillus (coprobacterium), Clostridium (Clostridium), Parabacteriaceae (Parabacteriaceae), Anaeroplasma (Anaeroplasma), and fecal coccus (Coprococcus);

preferably, the bacteria are selected from: one or more of Shigella, Streptococcus, Haemophilus, butyric acid vibrio, Callospiroceae, Brevibacillus, and Clostridium;

more preferably, the bacteria are selected from the group consisting of: specific sp.fc569, specific sp.fc1172, specific flexneri, specific sp.hmsc076h08, specific orisrista, specific sp.2015sissisi, specific gravity sp.2015 SSPC, specific gravity sp.hmsc073 h 12, specific gravity specimen sp, specific gravity specimen sp.20112, specific gravity specimen sp, specific gravity specimen sp.20120112, specific gravity specimen sp.20112, specific gravity specimen sp.200sp.20001, specific gravity specimen sp.hmsp.12, specific gravity specimen sp.069, specific gravity specimen sp.20112, specific gravity specimen sp.20120, specific gravity specimen sp.2001, specific gravity specimen sp.121, specific gravity specimen sp.8, specific gravity specimen sp.2001, specific gravity specimen sp.8, specific gravity specimen sp.12, specific gravity specimen sp.06sp.8, specific gravity specimen sp.2001, specific gravity specimen sp.8 Lachnospiraceae bacteria NLAE-zl-G231, Lachnospiraceae bacteria 2_1_46FAA, Lachnospiraceae bacteria MA2020, Lachnospiraceae bacteria NK3A20, Lachnospiraceae bacteria COE1, Lachnospiraceae bacteria MC2017, Lachnospiraceae bacteria 9_1_43BFAA, Lachnospiraceae bacteria P6B14, Lachnospiraceae bacteria F01-11, Lachnospiraceae bacteria A4, Lachnospiraceae bacteria ND 2012P 6A3, Lachnospiraceae bacteria AB 28-4, Lachnospiraceae bacteria XP 8, Lachnospiraceae bacteria N2001, Lachnospiraceae bacteria C2008, Lachnospiraceae bacteria C2001, Lacylace C2008, Lacylace C200sacandrum C13, Lacylaceae bacteria A4628-4, Lactobacillarum sp 23-11, Lactobacillicium B2001, Lactobacillicium C2001, Lactobacillicium Spiraceae C11, Lactobacillium C11, Lactobacilli A, Clostridium sp.14-2, Clostridium xylophilum, Clostridium plexicola, [ Eubacterium oxydoreducens, [ Eubacterium ] cellulolytics, [ Eubacterium ] cellulolyticus, Eubacterium rudimentum, Eubacterium uniflora, Eubacterium california gallinarium, [ Eubacterium ] strain, [ Eubacterium ] halidium, Eubacterium ventriosum, Brachyspira sp.sp.79, Brachyspira alvimentilla, Brachyspira innocens, Brachyspira chrysosporium, Brachyspira mycorrhidium, Brachyspira endophytica, Clostridium sporophydium, Clostridium sporophybacterium 1, Clostridium sporophytidum, Clostridium sporophybacterium 1, Clostridium sporophybacterium, Clostridium sporophyceae, Clostridium sporophybacterium 1, Clostridium sporophybacterium, Clostridium sporophyceae, Clostridium sporophybacterium 1, Clostridium sporophybacterium, Clostridium sporophybacterium 1, Clostridium sporophybacterium, Clostridium sporophybacterium 1, Clostridium sporophybacterium, Clostridium sporophybacterium 1, Clostridium sporophybacterium 1, Clostridium, One or a combination of two or more of Clostridium saccharolyticum, Clostridium saccharomicrobutylaceum, Clostridium freiginis, Clostridium sp.CL-2, Clostridium sp.DSM 8431, Clostridium septicum, Clostridium taeniosporium, Clostridium bacteria 1_7_47FAA, Clostridium perfringens, Clostridium sp.ND2, Clostridium neonatale, Clostridium genes, Clostridium sp.7_2_43FAA, Clostridium fallax, Clostridium bacteria 202-29, Clostridium hmatum. HM19aUC, Clostridium SCidium 202-09, Clostridium thermobutyricum, Clostridium parvularia 5.1-1, Clostridium sporobacter sp.25, Clostridium butyricum, Clostridium sp.12525, Clostridium sporobacter sp.04, Clostridium sporobacter sp.1-25, Clostridium sporobacter sp.1, Clostridium sporobacter sp.12, Clostridium butyricum, Clostridium sporobacter sp.12525, Clostridium sporobacter sp.12, Clostridium sporobacter sp.31, Clostridium sporobacter sp.25, Clostridium sporobacter sp.12, Clostridium sp.25, Clostridium sporobacter sp.12, Clostridium sp.25, Clostridium sp.12, Clostridium sp..

The use of the Chinese medicinal composition in regulating intestinal microorganisms can be selectively inhibiting the amount of viruses in the intestinal tract, wherein the viruses are selected from the following group: one or a combination of two or more of streptococcal virus (Streptococcus virus), enterococcal phage (Enterococcus phase), Lactobacillus phage (Lactobacillus phase), and Enterobacter phage (Enterobacteria phase);

preferably, the virus is selected from: streptococcal viruses;

more preferably, the virus is selected from: one or a combination of two of Streptococcus virus 7201 and Streptococcus virus C1.

The invention provides application of a traditional Chinese medicine composition in preparing a medicine, wherein the medicine is used for treating diseases related to intestinal flora disorder, and preferably, the diseases are selected from the following: chronic diarrhea, constipation, obesity, food allergy, pancreatitis, liver injury, intestinal inflammation including crohn's disease, irritable bowel syndrome, peptic ulcer, renal calculus, diabetes including gestational diabetes, rheumatoid arthritis, behcet's disease, cardiovascular disease, cerebrovascular disease including stroke, tumor, paralysis, eye disease, multiple sclerosis, ankylosing spondylitis, parkinson's disease, anxiety, autism, depression, chronic fatigue. The traditional Chinese medicine composition is medicinal powder of composition raw material medicines or an extract of the composition raw material medicines, and preferably, the traditional Chinese medicine composition is the extract of the composition raw material medicines.

The preparation method of the traditional Chinese medicine composition comprises the following steps:

(1) weighing the raw materials in a weight ratio;

(2) making into powder or extracting to obtain crude drug extract;

(3) the Chinese medicinal composition is prepared by mixing the medicinal powder or the extract of the raw material medicaments, or by adding one or more pharmaceutically acceptable auxiliary materials into the medicinal powder or the extract of the raw material medicaments.

Preferably, the Chinese medicine powder in the step (2) is obtained by crushing the raw material medicine to 200-1200 meshes; more preferably, the powder in step (2) is obtained by pulverizing the crude drug to 800-.

The extraction method in the step (2) is selected from: solvent extraction, percolation, decoction, reflux, continuous reflux, ultrasonic extraction, supercritical fluid extraction, steam distillation, sublimation, resin adsorption separation, and gel chromatography;

in a preferred embodiment of the invention, the extraction method is selected from: solvent extraction, decocting, and resin adsorption separation.

Drawings

FIG. 1 modified intestinal microbial species of the Astragalus membranaceus, Polygonatum sibiricum and Angelica composition

Detailed Description